SEARCH:   Advanced

Blood, 1 February 2008, Vol. 111, No. 3, pp. 1101-1109. Prepublished online as a Blood First Edition Paper on November 7, 2007; DOI 10.1182/blood-2007-05-090258. This Article Full Text (PDF) Supplemental Tables All Versions of this Article: blood-2007-05-090258v1 111/3/1101    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Niesvizky, R. Articles by Coleman, M. Search for Related Content PubMed PubMed Citation Articles by Niesvizky, R. Articles by Coleman, M. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted May 16, 2007 Accepted October 28, 2007 BiRD (Biaxin®[clarithromycin]/Revlimid®[lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma Ruben Niesvizky*, David S. Jayabalan, Paul J. Christos, Jessica R. Furst, Tara Naib, Scott Ely, Jessica Jalbrzikowski, Roger N. Pearse, Faiza Zafar, Karen Pekle, April LaRow, Richard Lent, Tomer Mark, Hearn J. Cho, Tsiporah Shore, Jeffrey Tepler, John Harpel, Michael W. Schuster, Susan Mathew, John P. Leonard, Madhu Mazumdar, Selina Chen-Kiang, and Morton Coleman Dept. of Medicine, Division of Hematology & Medical Oncology, Center of Excellence for Lymphoma and Myeloma, New York, NY, United States Department of Pathology, Weill-Cornell Medical College, New York Presbyterian Hospital-Cornell Medical Center, New York, NY, United States Dept. of Public Health, Div. of Biostatistics & Epidemiology, Weill-Cornell Medical College, New York Presbyterian Hospital-Cornell Medical Center, New York, NY, United States * Corresponding author; email: run9001{at}med.cornell.edu. The aim of this trial was to determine the safety and efficacy of the combination regimen clarithromycin (Biaxin®), lenalidomide (Revlimid®), and dexamethasone (BiRD) as first-line therapy for multiple myeloma. Patients received BiRD in 28-day cycles. Dexamethasone (40 mg) was given orally once weekly, clarithromycin (500 mg) was given orally twice daily, and lenalidomide (25 mg) was given orally daily on days 1-21. In cycle 1, patients received dexamethasone on 3 consecutive days, and lenalidomide was begun on day 3 for pharmacokinetic studies. Objective response was defined by standard criteria (i.e. decrease in serum monoclonal protein [M-protein] by 50%, and a decrease in urine M-protein by 90%). Of the 72 patients enrolled, 65 had an objective response (90.3%). A combined stringent and conventional complete response rate of 38.9% was achieved, and 73.6% of the patients achieved a 90% decrease in M-protein levels. This regimen did not interfere with hematopoietic stem cell harvest. Fifty-two patients who did not go on to receive transplantation received continued therapy (complete response 37%, very good partial response 33%). The major toxicities were thromboembolic events, corticosteroid-related morbidity, and cytopenias. BiRD is an effective regimen with manageable side effects in the treatment of symptomatic, newly diagnosed multiple myeloma. This trial was registered at www.ClinicalTrials.gov as #NCT00151203. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J.-L. Harousseau, H. Avet-Loiseau, M. Attal, C. Charbonnel, F. Garban, C. Hulin, M. Michallet, T. Facon, L. Garderet, G. Marit, et al. Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials J. Clin. Oncol., December 1, 2009; 27(34): 5720 - 5726. [Abstract] [Full Text] [PDF] J.-L. Harousseau, M. Attal, and H. Avet-Loiseau The role of complete response in multiple myeloma Blood, October 8, 2009; 114(15): 3139 - 3146. [Abstract] [Full Text] [PDF] S. Kumar, S. Giralt, E. A. Stadtmauer, J. L. Harousseau, A. Palumbo, W. Bensinger, R. L. Comenzo, S. Lentzsch, N. Munshi, R. Niesvizky, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens Blood, August 27, 2009; 114(9): 1729 - 1735. [Abstract] [Full Text] [PDF] D. Reece, K. W. Song, T. Fu, B. Roland, H. Chang, D. E. Horsman, A. Mansoor, C. Chen, E. Masih-Khan, Y. Trieu, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13 Blood, July 16, 2009; 114(3): 522 - 525. [Abstract] [Full Text] [PDF] J.-L. Harousseau and P. Moreau Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma N. Engl. J. Med., June 18, 2009; 360(25): 2645 - 2654. [Full Text] [PDF] D. Reece, J.-L. Harousseau, and M. A. Gertz Nontransplant Therapy of Myeloma, High-dose Therapy for Myeloma, and a Personalized Care Plan for Treatment of Myeloma ASCO Educational Book, January 1, 2009; 2009(1): 502 - 509. [Abstract] [Full Text] [PDF] J.-L. Harousseau Induction Therapy in Multiple Myeloma Hematology, January 1, 2008; 2008(1): 306 - 312. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020